Immune Responses to Mycobacterium Tuberculosis
NCT00340990 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 111
Last updated 2019-12-05
Summary
This study, conducted at the University of Mali in the capital city of Bamako, will investigate how the body reacts to infection with Mycobacterium tuberculosis (MTB), the organism that causes tuberculosis. Tuberculosis is a major global health problem whose solution requires development of an effective vaccine. However, incomplete understanding of how immunity to MTB is acquired and measured limits vaccine development. This study will focus on certain immune system cells - CD4+ T cells - that appear to be very important in fighting tuberculosis.
Individuals 16 years of age and older who have or have not been exposed to either tuberculosis or HIV, or both, may be eligible for this study. Candidates will be screened with a medical history, physical examination, blood tests, review of medical records and laboratory tests, and, if medically indicated, a chest x-ray. Individuals whose medical records indicate a past history of tuberculosis or a positive test for exposure to tuberculosis will have a tuberculin skin test. For this test, a few drops of fluid are placed under the skin to see if the immune system reacts to the substance, indicating previous exposure to MTB.
Participants will come to the University of Mali 10 times over a 1-year period - 7 times within the first 3 months of the study and then once every 3 months until 1 year after enrollment. At each study visit, they will be asked about their medical history and will donate 75 milliliters (about 1/3 cup) of blood, totaling 830 mL over the entire year. More blood may be requested if the participant's immune system reacts strongly to MTB in laboratory tests. No more than 450 mL (2 cups) of blood would be collected every 6 weeks; this amount is the Red Cross limit for regular blood donations every 6 weeks.
The blood samples will be used for tests that measure the level of immunity to tuberculosis. Genetic tests may be performed on blood cells to help interpret special tests of immunity. Because HIV-infected people are included in the study, the findings may also provide information on how HIV renders vulnerability to opportunistic infections, including tuberculosis.
Conditions
- Mycobacterium Tuberculosis
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Sophia B Siddiqui, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-10-06
- Completion
- 2015-11-27
Countries
- Mali
Study Locations
More Related Trials
-
The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis
NCT06580639 ·Status: RECRUITING
-
Immunocompetent Versus Immunocompromised Tuberculosis (TB) Patients
NCT06709157 ·Status: NOT_YET_RECRUITING
-
Oral Urea Breath Testing for Diagnosis and Treatment Response in Pulmonary Tuberculosis
NCT01301144 ·Status: COMPLETED
-
Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.
NCT00341328 ·Status: COMPLETED ·Phase: PHASE3
-
Delayed Diagnosis of Bacteriologically Positive Pulmonary Tuberculosis and Relative Optimized Suggestions in China
NCT04434976 ·Status: COMPLETED
-
Comorbidities and Coinfections in Latent TB
NCT04642755 ·Status: RECRUITING
-
Tuberculosis Immunity in Children
NCT00170638 ·Status: COMPLETED
-
Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
NCT05027958 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Lung Innate Immunity and Microbiome After Tuberculosis Exposure
NCT06526689 ·Status: RECRUITING
-
Expression of Tuberculosis in the Lung
NCT00201253 ·Status: COMPLETED
-
Deworming Against Tuberculosis
NCT00857116 ·Status: COMPLETED ·Phase: NA
-
Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis
NCT04930978 ·Status: RECRUITING
-
Potential Role of Microbiome in Tuberculosis
NCT04985994 ·Status: COMPLETED
-
Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients
NCT00265226 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of a Novel Microbiological Diagnostic Test for Latent Mycobacterium Tuberculosis Infection
NCT06728930 ·Status: ENROLLING_BY_INVITATION
-
Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis
NCT00173264 ·Status: UNKNOWN
-
Use TST and QFT-RD1 Test to Monitor the Tuberculous Infection in Patients, Close Contact People and Health Care Workers
NCT00311220 ·Status: UNKNOWN ·Phase: PHASE4
-
Identifcation of Biomarkers for Active Pulmonary Tuberculosis
NCT04490746 ·Status: UNKNOWN
-
Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
NCT04830462 ·Status: COMPLETED ·Phase: PHASE4
-
Diagnosis of Active and Latent TB Infection With IFN-y Assays in African Children
NCT00456469 ·Status: UNKNOWN
-
Cytometric Immunodiagnostics of Latent Tuberculosis Infection (LTBI)
NCT04673227 ·Status: UNKNOWN
-
Benin Population Diversity of Tuberculosis and Implications
NCT02744469 ·Status: COMPLETED
-
Study of GeneXpert Mycobacterium Tuberculosis/ Rifampicin (MTB/RIF) Versus the Routine Methods for Detection of Mycobacterium Tuberculosis
NCT06409572 ·Status: NOT_YET_RECRUITING
-
Pre- and Post-treatment Lung Microbiota, Metabolome and Immune Signatures at the Site of Disease in Patients With Active Pulmonary Tuberculosis
NCT04700579 ·Status: RECRUITING
-
Training Protocol on the Natural History of Tuberculosis
NCT01212003 ·Status: RECRUITING